Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...

Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of ...

A newly discovered brain protein linked to Parkinson’s offers hope for targeted therapies that could slow or prevent disease ...

Tofersen (BIIB067) is an ASO that is under investigation for the treatment of ALS caused by SOD1 mutations. Tofersen has been designed to mediate RNase H–dependent degradation of SOD1 mRNA to ...

The disease, which is caused by mutations in the SOD1 gene, accounts for approximately 10% to 20% of genetic ALS cases and 1% to 2% of sporadic ALS cases, according to the ALS Association. 7.

Could similar changes in SOD1 underlie both familial and sporadic ALS? Here, Bosco et al. find that wild-type SOD1 from sporadic ALS tissues shows conformational changes similar to those seen in ...

The U.S. Food and Drug Administration approved a new drug Tuesday to treat a rare form of amyotrophic lateral sclerosis, or ALS.. The drug Qalsody (tofersen) is expected to help people with a very ...

SOD1-G85 seems to act as a sort of “acceptor” for SOD1-propagated misfolding in a way that the wild-type protein does not. Cashman speculated that in an aging person, wild-type SOD1 might become more ...

In this phase 3 trial, we randomly assigned adults with SOD1 ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the ...